Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of GLSI is 46 and suggests 59% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell